Suchergebnisse - "Drug Repositioning"

PubPharm (19)

1

Host Cell Targets for Unconventional Antivirals against RNA Viruses

enthalten in: Viruses | 2023

von Roa-Linares, V. | Escudero-Flórez, M. | Vicente-Manzanares, M. | +1

2

Targeting Human Proteins for Antiviral Drug Discovery and Repurposing Efforts : A Focus on Protein Kinases

enthalten in: Viruses | 2023

von Hajjo, R. | Sabbah, D. | Abusara, O. | +2

3

In-vitro antiviral activity of doxepin hydrochloride against group B coxsackievirus

enthalten in: Virus research | 2022

von Yang, Y. | Liu, G. | Jia, J. | +5

4

Systematic optimization of host-directed therapeutic targets and preclinical validation of repositioned antiviral drugs

enthalten in: Briefings in bioinformatics | 2022

von Xie, D. | He, S. | Han, L. | +7

5

DeepVir : Graphical Deep Matrix Factorization for In Silico Antiviral Repositioning-Application to COVID-19

enthalten in: Journal of computational biology : a journal of computational molecular cell biology | 2022

von Mongia, A. | Jain, S. | Chouzenoux, E. | +1

6

A network representation approach for COVID-19 drug recommendation

enthalten in: Methods (San Diego, Calif.) | 2022

von Liu, H. | Lin, H. | Shen, C. | +6

7

Computationally prioritized drugs inhibit SARS-CoV-2 infection and syncytia formation

enthalten in: Briefings in bioinformatics | 2022

von Serra, A. | Fratello, M. | Federico, A. | +16

8

A deep learning method for repurposing antiviral drugs against new viruses via multi-view nonnegative matrix factorization and its application to SARS-CoV-2

enthalten in: Briefings in bioinformatics | 2022

von Su, X. | Hu, L. | You, Z. | +3

9

Identifying FDA-approved drugs with multimodal properties against COVID-19 using a data-driven approach and a lung organoid model of SARS-CoV-2 entry

enthalten in: Molecular medicine (Cambridge, Mass.) | 2021

von Duarte, R. | Copertino, D. | Iñiguez, L. | +7

10

Can drug repurposing strategies be the solution to the COVID-19 crisis?

enthalten in: Expert opinion on drug discovery | 2021

von Bellera, C. | Llanos, M. | Gantner, M. | +4